Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manish R Patel

Showing results (51-60 of 167) with videos related to

Pageof 17
Sort By:
Oncotarget|October 4, 2017
Cap-dependent translational control of oncolytic measles virus infection in malignant mesotheliomaBlake A Jacobson, Ahad A Sadiq, Shaogeng Tang, et al.
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|March 7, 2020
Nutrition Status and Health-Related Quality of Life Among Outpatients With Advanced Head and Neck CancerUrvashi Mulasi, David M Vock, Harriët Jager-Wittenaar, et al.
Journal for Immunotherapy of Cancer|November 21, 2020
Efficacy and immune-related adverse event associations in avelumab-treated patientsKaren Kelly, Juliane Manitz, Manish R Patel, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2015
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Cancer Gene Therapy|November 14, 2018
Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancerArpita De, Blake A Jacobson, Mark S Peterson, et al.
Cancer Discovery|June 3, 2023
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation StudyPatricia LoRusso, Noboru Yamamoto, Manish R Patel, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumoursManish R Patel, Melissa Johnson, Ira Winer, et al.
Investigational New Drugs|April 9, 2014
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cellsEsther Z Chen, Blake A Jacobson, Manish R Patel, et al.
Targeted Oncology|November 19, 2024
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid TumorsManish R Patel, Gerald S Falchook, Judy S Wang, et al.
Gastrointestinal Cancer Research : GCR|February 28, 2012
Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic CancerMichael D Chuong, Tom J Hayman, Manish R Patel, et al.
Pageof 17

Showing results (51-60 of 167) with videos related to

Sort By:
Pageof 17
Oncotarget|October 4, 2017
Cap-dependent translational control of oncolytic measles virus infection in malignant mesotheliomaBlake A Jacobson, Ahad A Sadiq, Shaogeng Tang, et al.
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|March 7, 2020
Nutrition Status and Health-Related Quality of Life Among Outpatients With Advanced Head and Neck CancerUrvashi Mulasi, David M Vock, Harriët Jager-Wittenaar, et al.
Journal for Immunotherapy of Cancer|November 21, 2020
Efficacy and immune-related adverse event associations in avelumab-treated patientsKaren Kelly, Juliane Manitz, Manish R Patel, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2015
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Cancer Gene Therapy|November 14, 2018
Inhibition of oncogenic cap-dependent translation by 4EGI-1 reduces growth, enhances chemosensitivity and alters genome-wide translation in non-small cell lung cancerArpita De, Blake A Jacobson, Mark S Peterson, et al.
Cancer Discovery|June 3, 2023
The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation StudyPatricia LoRusso, Noboru Yamamoto, Manish R Patel, et al.
Cancer Immunology, Immunotherapy : CII|March 30, 2024
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumoursManish R Patel, Melissa Johnson, Ira Winer, et al.
Investigational New Drugs|April 9, 2014
Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cellsEsther Z Chen, Blake A Jacobson, Manish R Patel, et al.
Targeted Oncology|November 19, 2024
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid TumorsManish R Patel, Gerald S Falchook, Judy S Wang, et al.
Gastrointestinal Cancer Research : GCR|February 28, 2012
Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic CancerMichael D Chuong, Tom J Hayman, Manish R Patel, et al.
Pageof 17